Difference Capital Announces Results of its Annual Meeting of Shareholders
TORONTO, June 27, 2018 (GLOBE NEWSWIRE) -- Difference Capital Financial Inc. (“DCF” or the “Company”) (TSX:DCF) (TSX:DCF.DB) reported the results of its Annual Meeting of the Company’s shareholders (the “Shareholders”) held in Toronto, Ontario on June 27, 2018 (the “Meeting”). DCF is pleased to announce that all resolutions put forward in the Management Information Circular dated May 25, 2018 (the “Circular”) to Shareholders were approved.
At the Meeting, each of the following five nominees proposed by management was elected as a director of DCF:
| Director | Vote Type | Number of Votes | Percentage of Votes |
| Michael Wekerle | For Withheld | 1,281,197 82,411 | 93.96% 6.04% |
| Henry Kneis | For Withheld | 1,286,157 77,451 | 94.32% 5.68% |
| Wayne Gudbranson | For Withheld | 1,286,117 77,491 | 94.32% 5.68% |
| Corey Delaney | For Withheld | 1,286,117 77,491 | 94.32% 5.68% |
| Kees Van Winters | For Withheld | 1,281,157 82,451 | 93.95% 6.05% |
In addition, at the Meeting, Shareholders reappointed Ernst & Young LLP as auditors of the Company.
For further details of each of the above matters, please refer to the Circular filed on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.
About Difference Capital Financial Inc.
Difference Capital Financial Inc. invests in and advises growth companies. We leverage our capital market expertise to help unlock the value in technology, media and healthcare companies as they approach important milestones in their business lifecycle.
Contact Information
Difference Capital Financial Inc.
Henry Kneis
Chief Executive Officer
(416) 649-5085
www.differencecapital.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
U.S. FDA Approves Gilead Sciences' (Nasdaq: GILD) Antiviral Veklury (remdesivir) for the Treatment of COVID-19
